Impact

Introduction Across Oxford Health NHS Foundation Trust’s research infrastructures, the Trust’s Research and Delivery teams, the NIHR Oxford Health Clinical Research Facility (OH CRF), NIHR Oxford Health Biomedical Research Centre (OH BRC) and the NIHR Mental Health Translational Research ... Read More

During the last 12 months, Oxford Health Clinical Research Facility (OH CRF) has opened its doors to facilitate media filming for local and national news outlets, highlighting a selection of of the mental health studies running at Oxford Health NHS Foundation Trust (OHFT), that the Facility ... Read More

Oxford Health Clinical Research Facility (OH CRF) working in partnership with the University of Oxford is one of 18 centres supporting the national National Institute for Health and Care Research (NIHR) BioResource facilities in England. Led by Professor Philip McGuire, the Oxford Health ... Read More

As part of its sustainability efforts, the Clinical Research Facility (OH CRF) has donated expired but still usable medical supplies including syringes, cannulas, dressings, and blood tubes, to Tiggywinkles Wildlife Hospital. These items, no longer suitable for human clinical use, will now support ... Read More

Oxford Health NHS Foundation Trust's Mental Health Research Delivery Team have successfully recruited the first participants to the ASCEnD study into bipolar disorder, which is being carried out at the Oxford Health Clinical Research Facility (OH CRF). The ASCEnD study aims to address the limited ... Read More

The ReTain study at the Oxford Health Clinical Research Facility (OH CRF) is looking for volunteers aged 55-75 without a memory condition to evaluate the safety and effectiveness of an immunotherapy treatment in slowing the progression of Alzheimer’s Disease. Participation ... Read More

Recently, the NIHR Oxford Health Clinical Research Facility (OH CRF) has begun researching a new potential drug treatment for Treatment-Resistant Depression. A significant number of people with depression are not helped by at least two antidepressant medications. This is known as ... Read More

Recently, Oxford Academic Health Partners (OAHP) published a case study focusing on OH CRF's growing and diverse portfolio of studies and highly skilled staff, how we work across the National and Oxford research landscape and what our vision is for the future. The case study includes input and ... Read More

Recently, Oxford Health NHS Foundation Trust (OHFT) Director of Research and Development, Professor Vanessa Raymont featured on the BBC discussing the new READ-OUT dementia study, which opens at the Trust this month. The READ-OUT study is a national multi-site study in collaboration ... Read More

Professor Andrea Cipriani, Professor of Psychiatry at the University of Oxford and Director of the NIHR Oxford Health Clinical Research Facility (OH CRF), has led on a study which analysed treatments for tardive dyskinesia (TD) in people with schizophrenia or mood disorders. TD is a ... Read More

Dementia is widely recognised as one of the largest global public health challenges and the most common cause of dementia is Alzheimer’s Disease (AD). In 2022, dementia and Alzheimer's disease was the leading cause of death in the UK and with approximately 33% of the UK population aged fifty or ... Read More

Recently, the NIHR Oxford Health Clinical Research Facility (OH CRF) has begun researching a new potential drug treatment for Treatment-Resistant Depression (TRD). A significant number of people with depression are not helped by at least two antidepressant medications. This is known as ... Read More

Triptans, a drug usually offered as an alternative to painkillers, have been found to be the most effective medicine for adults who experience acute migraines. Findings of a study, which recruited over 89,000 participants, compared 17 oral medications commonly used to treat migraines were ... Read More

This week, a product licence for the medicine lecanemab (Leqembi) was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adult patients in the early stages of Alzheimer’s disease. The medication has shown some evidence of efficacy in slowing progression of the ... Read More

People with depression are being invited to be part of a clinical trial testing a new evidence-based AI treatment tool to personalise antidepressant treatment. The revolutionary digital tool, called PETRUSHKA, has been developed and is being trialled by a team at the University of Oxford’s ... Read More

Recently, both Oxford BRCs hosted a joint public talk at the University of Oxford’s Department for Continuing Education in Oxford. Professors Andrea Cipriani and Eva Morris discussed how patient data can transform diagnosis, treatment and care in the NHS. In the talk Professor of Health ... Read More

The University of Oxford and Oxford Health Clinical Research Facility  is part of country-wide trials to identify accurate and quick blood tests that can diagnose dementia. World-class research teams at Dementias Platform UK based at the Department of Psychiatry, University of ... Read More

Alzheimer’s Disease is a type of dementia in which abnormal proteins, called beta-amyloid and tau, accumulate in the brain and damage nerve cells. People with Alzheimer’s Disease often have trouble thinking, speaking, remembering things, and performing their daily activities. This condition is ... Read More

COmBining memantine And cholinesterase inhibitors in Lewy body dementia Treatment trial (COBALT) The Memory & Cognition Research Delivery Team at Oxford Health NHS Foundation Trust are looking for participants for a medical research trial. The trial will look at the use of a drug called ... Read More